Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 versus investigator's choice chemotherapy in previously treated advanced or metastatic urothelial carcinoma
CTR20244748Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-A2102 in transitional cell carcinoma (TCC), sponsored by Hengrui Therapeutics. Started Mar 2025; status: active.
02
Drugs
SHR-A2102
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20244748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244748.